Alexandre Le Vert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company’s OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebo-controlled, Phase 2a trial.” The research article presents results of the study evaluating the safety and immunogenicity of OVX836, a broad-spectrum influenza vaccine,...

Dr. Bille will oversee manufacturing scale-up for broad-spectrum influenza vaccine candidate OVX836 currently in Phase 2 clinical testingCompany achieved accreditation from Belgian authorities for OVX836 batch quality control laboratory in Liège Science ParkLYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical...

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has secured EUR 10M from

Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003)

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research